International Stem Cell Corporation (ISCO) Stock Price, News, Quote & History

International Stem Cell Corporation (ISCO) Stock Price, News, Quote & History - Yahoo Finance (2025)

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(Wt)}else s.style.display="block"},f=function(){d.refreshPanel().then(m).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(f(),setInterval((function(){f()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var h=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(to=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===h&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Jt)),notifLabel:document.querySelector(".".concat(Vt))};io(e,n)}))}()}};

OTC Markets OTCQB - Delayed Quote • USD

Compare

0.0900 +0.0190 (+26.76%)

At close: September 27 at 3:30 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for ISCO

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

Previous Close 0.0710
Open 0.0900
Bid 0.0600 x --
Ask 0.0950 x --
Day's Range 0.0900 - 0.0900
52 Week Range 0.0500 - 0.1500
Volume 700
Avg. Volume 1,842
Market Cap (intraday) 720,395
Beta (5Y Monthly) 0.18
PE Ratio (TTM) --
EPS (TTM) -0.0600
Earnings Date Aug 13, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est --

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and Alzheimer's disease. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also consists of adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

www.internationalstemcell.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about International Stem Cell Corporation

Recent News: ISCO

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

ISCOInternational Stem Cell Corporation

0.0900

+26.76%

Mkt Cap 720,395

Industry Biotechnology

LCTX.TALineage Cell Therapeutics, Inc.

328.60

-4.45%

Mkt Cap ILA 620.518M

Industry Biotechnology

CASICASI Pharmaceuticals, Inc.

6.01

+3.98%

Mkt Cap 92.921M

Industry Biotechnology

MRKRMarker Therapeutics, Inc.

2.9000

+5.45%

Mkt Cap 25.876M

Industry Biotechnology

NNVCNanoViricides, Inc.

1.4500

+2.11%

Mkt Cap 17.13M

Industry Biotechnology

LCTXLineage Cell Therapeutics, Inc.

0.9200

+6.75%

Mkt Cap 173.73M

Industry Biotechnology

Statistics: ISCO

Valuation Measures

Annual

As of 9/27/2024

Market Cap

720.39k
Enterprise Value

3.55M
Trailing P/E

4.67
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

0.09
Price/Book (mrq)

--
Enterprise Value/Revenue

0.43
Enterprise Value/EBITDA

166.00

Financial Highlights

Profitability and Income Statement

Profit Margin

-8.22%
Return on Assets (ttm)

-6.04%
Return on Equity (ttm)

-185.37%
Revenue (ttm)

8.32M
Net Income Avi to Common (ttm)

-467k
Diluted EPS (ttm)

-0.0600

Balance Sheet and Cash Flow

Total Cash (mrq)

1.29M
Total Debt/Equity (mrq)

1,447.54%
Levered Free Cash Flow (ttm)

2.38k

Research Analysis: ISCO

Company Insights: ISCO

Research Reports: ISCO

People Also Watch

BTIM Boatim Inc.

0.0001

0.00%

MCET MultiCell Technologies, Inc.

0.0000

0.00%

CCEL Cryo-Cell International, Inc.

6.48

-0.77%

NNVC NanoViricides, Inc.

1.4500

+2.11%

BCLI Brainstorm Cell Therapeutics Inc.

0.2225

-12.57%

IMUC EOM Pharmaceuticals Holdings, Inc.

0.1170

0.00%

PVCT Provectus Biopharmaceuticals, Inc.

0.0980

+0.31%

AMBS Amarantus BioScience Holdings, Inc.

0.0001

0.00%

GALT Galectin Therapeutics Inc.

2.7100

+2.26%

USRM U.S. Stem Cell, Inc.

0.0001

0.00%

RGRX RegeneRx Biopharmaceuticals, Inc.

0.0014

0.00%

IGXT IntelGenx Technologies Corp.

0.1700

0.00%

ELTP Elite Pharmaceuticals, Inc.

0.3900

0.00%

AOLS Aeolus Pharmaceuticals, Inc.

0.0001

0.00%

XDSL mPhase Technologies, Inc.

0.0001

0.00%

NPHC Nutra Pharma Corp.

0.0001

0.00%